[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100176262":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":26,"responsibleParty":37,"collaborators":11,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":11,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":11,"enrollmentInfo":48,"targetDuration":11,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":11,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Laboratoires Thea","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"T2750","EXPERIMENTAL",null,[13],"Device: T2750",{"label":15,"type":16,"description":11,"interventionNames":17},"Vismed","ACTIVE_COMPARATOR",[18],"Device: Vismed",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DEVICE","1 drop in each eye 3 to 6 times daily during 84 days",[9],{"type":21,"name":15,"description":22,"armGroupLabels":25,"otherNames":11},[15],[27],{"facility":11,"status":11,"city":28,"state":11,"zip":11,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":11},"Paris","France","FR",{"type":32,"coordinates":33},"Point",[34,35],2.3488,48.85341,{"lat":35,"lon":34},{"type":38,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100176262","phase-3-comparison-of-the-efficacy-and-safety-of-t2750-and-vismed-in-the-treatment-of-moderate-to-severe-dry-eye-syndrome-100176262",true,"NCT01568593","Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome","Inclusion Criteria:\n\n* Signed and dated informed consent\n* Male or female aged from ≥ 18 years old.\n* Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study selection.\n\nExclusion Criteria:\n\n* Best far corrected visual acuity \\\u003C 1\u002F10\n* Severe blepharitis\n* Severe Dry Eye\n* Eyelid malposition\n* Known hypersensitivity to one of the components of the study medications or test products.\n* Pregnant or breast-feeding woman.\n* Woman of childbearing age (neither menopausal, nor hysterectomised, nor sterilized) not using effective contraception (oral contraceptives, intra-uterine device, contraceptive implant or condoms).\n* Inability of patient to understand the study procedures and thus inability to give informed consent.\n* Non compliant patient (e.g. not willing to attend the follow-up visits, way of life interfering with compliance).\n* Already included once in this study.\n* Patient under guardianship.",false,"ALL","18 Years",{"count":49,"type":50},93,"ACTUAL","INTERVENTIONAL",[53],"PHASE3","Comparison of the efficacy and safety of T2750 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome",[56],"Dry Eye Syndromes","COMPLETED","2016-03-07",{"date":60,"type":61},"2016-04-04","ESTIMATED",{"date":63,"type":11},"2012-03",{"date":65,"type":50},"2013-03",{"name":5,"class":6},1]